[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Milestone Pharmaceuticals Inc (MIST)

Milestone Pharmaceuticals Inc (MIST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 144,418
  • Shares Outstanding, K 124,498
  • Annual Sales, $ 1,550 K
  • Annual Income, $ -63,060 K
  • EBIT $ -80 M
  • EBITDA $ -80 M
  • 60-Month Beta 0.98
  • Price/Sales 95.83
  • Price/Cash Flow N/A
  • Price/Book 8.13

Options Overview Details

View History
  • Implied Volatility 226.16% (+105.12%)
  • Historical Volatility 71.13%
  • IV Percentile 54%
  • IV Rank 25.98%
  • IV High 652.40% on 03/30/26
  • IV Low 76.52% on 05/15/26
  • Expected Move (DTE 19) 0.2550 (21.98%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 112
  • Volume Avg (30-Day) 631
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 27,434
  • Open Int (30-Day) 23,487
  • Expected Range 0.9050 to 1.4150

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.20
  • Number of Estimates 4
  • High Estimate $-0.16
  • Low Estimate $-0.22
  • Prior Year $-0.12
  • Growth Rate Est. (year over year) -66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0100 +14.85%
on 07/29/26
1.2900 -10.08%
on 08/11/26
+0.0900 (+8.41%)
since 07/28/26
3-Month
1.0100 +14.85%
on 07/29/26
1.4550 -20.27%
on 05/29/26
-0.2800 (-19.44%)
since 05/28/26
52-Week
1.0000 +16.00%
on 03/30/26
3.0600 -62.09%
on 12/12/25
-0.6500 (-35.91%)
since 08/28/25

Most Recent Stories

More News
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes

Research Shows that Patients with PSVT Experience a Substantial Burden Between Episodes, with Negative Impacts on Anxiety, Daily Activities, Sleep, and...

MIST : 1.1600 (-2.52%)
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes

MONTREAL and CHARLOTTE, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 1.1600 (-2.52%)
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT) Research Builds...

MIST : 1.1600 (-2.52%)
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT) Research Builds on Phase 2 Findings that Etripamil 70 mg...

MIST : 1.1600 (-2.52%)
Milestone Pharmaceuticals: Q2 Earnings Snapshot

Milestone Pharmaceuticals: Q2 Earnings Snapshot

MIST : 1.1600 (-2.52%)
Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST ® (etripamil) nasal spray Phase 3 registrational trial of etripamil...

MIST : 1.1600 (-2.52%)
Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST® (etripamil) nasal spray

MIST : 1.1600 (-2.52%)
Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

MONTREAL and CHARLOTTE, N.C., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on...

MIST : 1.1600 (-2.52%)
Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

MONTREAL and CHARLOTTE, N.C., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 1.1600 (-2.52%)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards,...

MIST : 1.1600 (-2.52%)

Business Summary

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 1.2617
2nd Resistance Point 1.2333
1st Resistance Point 1.1967
Last Price 1.1600
1st Support Level 1.1317
2nd Support Level 1.1033
3rd Support Level 1.0667

See More

52-Week High 3.0600
Fibonacci 61.8% 2.2731
Fibonacci 50% 2.0300
Fibonacci 38.2% 1.7869
Last Price 1.1600
52-Week Low 1.0000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.